BeOne Medicines (ONC) Short-term Investments (2015 - 2023)

BeOne Medicines (ONC) has 9 years of Short-term Investments data on file, last reported at $2.6 million in Q4 2023.

• Quarterly Short-term Investments fell 99.61% year-over-year to $2.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.6 million (down 99.61% YoY) and the FY2023 annual result came in at $2.6 million, down 99.61% from the prior year.
• Short-term Investments fell to $2.6 million in Q4 2023 per ONC's latest filing, from $107.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $3.3 billion in Q4 2020 and bottomed at $2.6 million in Q4 2023.
• The 5-year median for Short-term Investments is $1.0 billion (2022), against an average of $1.4 billion.
• The widest annual swing landed in 2020, when Short-term Investments jumped 796.21%; it then sank 99.61% in 2023.
• Tracing ONC's Short-term Investments over 5 years: stood at $364.7 million in 2019, then jumped by 796.21% to $3.3 billion in 2020, then slumped by 31.41% to $2.2 billion in 2021, then plunged by 70.33% to $665.3 million in 2022, then slumped by 99.61% to $2.6 million in 2023.
• Per Business Quant, the three latest ONC Short-term Investments figures stand at $2.6 million (Q4 2023), $107.0 million (Q3 2023), and $105.7 million (Q2 2023).

Peer Comparison